Filing Details
- Accession Number:
- 0001140361-17-018657
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-05-05 18:11:09
- Reporting Period:
- 2017-05-03
- Filing Date:
- 2017-05-05
- Accepted Time:
- 2017-05-05 18:11:09
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 874716 | Idexx Laboratories Inc | IDXX | In Vitro & In Vivo Diagnostic Substances (2835) | 010393723 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1254748 | M Rebecca Henderson | One Idexx Drive Westbrook ME 04092 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2017-05-04 | 6,602 | $38.80 | 21,552 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2017-05-04 | 1,700 | $159.95 | 19,852 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Deferred Stock Unit | Acquisiton | 2017-05-03 | 289 | $0.00 | 289 | $0.00 |
| Common Stock | Non-Qualified Stock Option (right-to-buy) | Acquisiton | 2017-05-03 | 3,046 | $0.00 | 3,046 | $160.28 |
| Common Stock | Non-Qualified Stock Option (right-to-buy) | Disposition | 2017-05-04 | 6,602 | $0.00 | 6,602 | $38.80 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 17,094 | No | 4 | A | Direct | ||
| 3,046 | 2027-05-02 | No | 4 | A | Direct | |
| 0 | 2018-02-13 | No | 4 | M | Direct |
Footnotes
- Represents the weighted average sales price of the shares sold ranging from a low of $159.9110 to a high of $159.9718 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2018 annual meeting of stockholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.
- Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on May 3, 2018.
- Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 3,301 shares on February 14, 2012, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split").? The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
- Not applicable.
Billionaire Hedge Funds
